TELA Bio, Inc. Form 10-Q Summary
Business Context and Reporting Period
TELA Bio is a commercial-stage medical technology company focused on soft-tissue reconstruction products, primarily OviTex and OviTex PRS reinforced tissue matrices. The unaudited report covers the three months ended March 31, 2024, compared with the three months ended March 31, 2023. The company markets primarily in the United States through a direct sales force and has operations in Europe.
Financial Performance and Position
| Metric | Q1 2024 | Q1 2023 | Change |
|---|---|---|---|
| Revenue | $16.6 million | $11.9 million | Up 39% |
| Gross profit | $11.3 million | $7.9 million | Up 44% |
| Gross margin | 68% | 66% | Up 2 percentage points |
| Operating expenses | $23.7 million | $19.2 million | Up 24% |
| Loss from operations | $4.8 million | $11.3 million | Improved by $6.4 million |
| Net loss | $5.7 million | $12.0 million | Improved by 53% |
| Basic and diluted loss per share | $0.23 | $0.63 | Improved |
| Cash used in operating activities | $14.4 million | $11.6 million | Use increased by $2.8 million |
Revenue growth was driven by higher unit sales, new customers, greater penetration of existing accounts and international sales. OviTex revenue was $10.5 million, up from $8.0 million, while OviTex PRS revenue was $5.9 million, up from $3.9 million. OviTex unit volume increased 35% and OviTex PRS unit volume increased 57% year over year.
Sales and marketing expense increased 30% to $17.5 million as the commercial organization expanded. General and administrative expense increased 5% to $3.8 million, and research and development expense increased 17% to $2.4 million. Interest expense increased 7% to $1.3 million because of the higher variable interest component.
At March 31, 2024, cash and cash equivalents were $37.1 million, compared with $46.7 million at December 31, 2023. Working capital was $47.4 million, compared with $54.8 million at year-end. Total assets were $71.8 million and stockholders’ equity was $14.4 million. The accumulated deficit was $326.6 million.
Long-term debt was $40.7 million, consisting primarily of a $40.0 million MidCap term loan. The loan matures in May 2027 and bears interest at 6.25% plus the greater of one-month Term SOFR or 1.0%. It is secured by substantially all company assets, including intellectual property, and is subject to quarterly minimum-revenue covenants and other restrictions.
Material Changes Versus the Prior Comparable Period
- Revenue increased 39%, while gross margin improved from 66% to 68%.
- Operating expenses increased 24%, primarily from expanded sales and marketing activities.
- Net loss decreased by $6.4 million, largely because of a $7.6 million gain on the sale of the NIVIS product line.
- Operating cash use increased to $14.4 million despite the lower net loss, reflecting working-capital changes and the noncash nature of the NIVIS gain.
- Cash declined by $9.6 million during the quarter, partly offset by $5.0 million of proceeds from the NIVIS transaction.
- The company launched the full commercial distribution of LiquiFix hernia mesh fixation devices in the United States in March 2024 and launched OviTex IHR in April 2024.
Guidance, Outlook, Commentary, Risks and Unusual Items
Management expects continued losses in the near term as it invests in sales, marketing, research and development and expansion into existing and new markets. Based on its current business plan, management believes existing cash resources will fund capital requirements and operations for at least the next 12 months from the filing date. Management also expects operating cash use to decrease during the remaining 2024 interim periods primarily because of forecast revenue growth. No specific revenue or earnings guidance was provided.
In March 2024, TELA Bio sold certain NIVIS distribution rights and related assets to MiMedx for an initial $5.0 million payment and potential future revenue-sharing payments ranging from $3.0 million to $7.0 million over the first two years following launch. The company recognized a $7.6 million gain and recorded the $3.0 million minimum future payment as a receivable, including $2.7 million classified as long-term. This transaction materially benefited reported operating results and is not indicative of recurring product sales.
Key risks include recurring losses and negative operating cash flow, the need for additional financing, potential dilution under the $50 million at-the-market program, debt covenant compliance, floating-rate interest exposure, reliance on exclusive contract manufacturer Aroa Biosurgery, supply-chain integrity, reimbursement and pricing pressure, regulatory approvals, product liability, competition, hospital staffing and procedure volumes, macroeconomic conditions and geopolitical events. The filing states that there were no material changes to the risk factors disclosed in the 2023 Form 10-K, no material legal proceedings and no off-balance-sheet arrangements.
Important Facts for Investors to Verify
- Whether revenue growth and unit-volume gains continue after the first-quarter comparison and without reliance on nonrecurring transactions.
- The sustainability of the 68% gross margin, including inventory excess and obsolescence charges and Aroa-related product costs.
- Cash burn, liquidity runway and the timing or likelihood of additional equity or debt financing.
- Compliance with the MidCap loan’s quarterly minimum-revenue covenants and the effect of floating interest rates on future interest expense.
- The timing and collectibility of the $3.0 million minimum NIVIS revenue-share receivable and any additional payments up to $7.0 million.
- Commercial adoption and reimbursement for OviTex, OviTex PRS, OviTex IHR and LiquiFix, including international sales trends.
- Dependence on Aroa for manufacturing, supply availability and regulatory clearances for OviTex products.